TNFSF11 and cancer: In addition, the prevalence of osteocytes expressing RANKL is increased in bones involved with myeloma cells (see the section “osteocytes and their derived factors as targets for the treatment of cancer that grows in bone”).79 Furthermore, myeloma cells increase the expression of IL‐11 in osteocytes, a cytokine that favors osteoclast differentiation.80 Thus, it is possible that by secreting pro‐osteoclastogenic cytokines and stimulating bone resorption, osteocytes contribute to the release of growth factors from the matrix fueling tumor growth.